If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.


_____ Brought to you by Avantor _____

How COVID-19 will change how we do science (Part 2 of 2)



  August 6, 2020

  8:00 a.m. PDT, 11:00 a.m. EDT, 16:00 BST, 17:00 CEST




From the earliest days of the still-unfolding COVID-19 pandemic, scientists mobilized like never before. Researchers worked collaboratively in unprecedented numbers across institutions and corporations to understand how the new virus works and to explore the potential for existing drugs to take it down. Companies are getting new diagnostics, vaccines, and treatments into the clinic at lightning speed. Scientists are publishing results on preprint servers practically in real time and using social media to communicate their findings.

Science has never moved faster. C&EN is holding a series of conversations with thought leaders across pharma and the life sciences to learn how the pandemic has transformed science⁠—and which changes are here to stay.

In the second of these webinars, we will hear from Christos Kyratsous, Vice President of Infectious Disease Research at Regeneron Pharmaceuticals, about how his group developed the first experimental monoclonal antibody cocktail for SARS-CoV-2, which is now in advanced clinical studies. We will also hear from Luk H. Vandenberghe, Associate Professor at Harvard Medical School, who is leading a multi-institutional, academic-industry partnership to develop an experimental vaccine for COVID-19 inspired by gene therapy. We hope you will join us for an exciting discussion about how these programs moved so quickly, and how the pandemic could impact the future of drug and vaccine development, hosted by C&EN's Ryan Cross.

Brought to you by:


Key Learning Objectives

  • The key technologies that enabled pharma to accelerate drug and vaccine development and manufacturing timelines
  • How lessons learned during the pandemic could accelerate drug and vaccine development in the future
  • How scientific collaboration has changed and how we'll disseminate our science in the future

Who Should Attend

  • Medicinal chemists
  • Process chemists
  • New product developers


Christos Kyratsous
Vice President of Research,
Infectious Diseases and Viral Vector Technologies at Regeneron Pharmaceuticals
Luk H. Vandenberghe, PhD
Associate Professor at Harvard Medical School,
Associate Member of the Broad Institute of Harvard and MIT in Boston, MA


Ryan Cross
Associate Editor, Biotech and Pharma